A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies

Project: Research

Project Details

Project Description

HREC Reference Number: HREC/22/QCHQ/90374
SSA Reference Number: SSA/90374/MonH-2023-354038(v1)
Monash Health Local Reference: RES-23-0000-117X
ERM Number: 90374
StatusActive
Effective start/end date29/03/23 → 28/03/28